Semaglutide

GLP-1

Compounding status of Semaglutide — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.

Current federal standing

On FDA’s 503B clinical-need list — under review

as of Jun 26, 2026

We do not sell, source, or supply Semaglutide. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

Jun 26, 2026503B bulks listFederal
Federal action on record
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
2026-12937 · primary source ↗
May 1, 2026503B bulks listFederal
Federal action on record
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
2026-08552 · primary source ↗

State overlays

No state-specific position on Semaglutide tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track Semaglutide changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.